Aruna Bio to Present at the 31st Annual Piper Jaffray Healthcare Conference

Presentation will highlight the ability of Aruna Bio’s proprietary neural exosomes to cross the blood brain barrier and function as a therapeutic and delivery vehicle for treating neurodegenerative diseases and stroke

ATHENS, GA & RESEARCH TRIANGLE PARK, NC--()--Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced that Dr. Mark Sirgo, Chief Executive Officer, and Dr. Steve Stice, Chief Scientific Officer, will be presenting at the 31st Annual Piper Jaffray Healthcare Conference in New York City on Thursday, December 5th at 8:10 AM Eastern time.

Drs. Sirgo and Stice will discuss the utilization of neural exosomes as both a therapeutic and a delivery vehicle to treat neurodegenerative diseases and stroke. The presentation will include data on Aruna Bio’s proprietary neural exosome platform, which has demonstrated therapeutic benefit in multiple animal models of stroke and is also being developed for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Dr. Sirgo will also discuss the company’s going forward strategy and key milestones for 2020.

About Aruna Bio
Aruna Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. Aruna Bio is also leveraging its proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing exosomes with RNA, oligonucleotides, antibodies and small molecules. www.arunabio.com

Contacts

Nick Chang, 781-235-3060
nchang@macbiocom.com

Release Summary

Aruna Bio, Inc. today announced that Dr. Mark Sirgo and Dr. Steve Stice will be presenting at the 31st Annual Piper Jaffray Healthcare Conference.

Contacts

Nick Chang, 781-235-3060
nchang@macbiocom.com